Clinical Trial Update: Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) [Phase 1]

View source ↗

Summary

Phase 1 trial of intratumoral/intralesional MK-4621/JetPEI with or without pembrolizumab in advanced/metastatic or recurrent solid tumors; study terminated with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• MK-4621 (MK-4621)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Solid Tumors | Phase 1 | Status: TERMINATED | Results posted: 2022-02-28